ID   697
AC   CVCL_0079
AS   CVCL_8861
SY   Line 697; EU-3; Emory University-3
DR   BTO; BTO:0001969
DR   CLO; CLO_0001008
DR   CLDB; cl117
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   BioSample; SAMN03473591
DR   BioSample; SAMN10988566
DR   Cell_Model_Passport; SIDM01076
DR   ChEMBL-Cells; CHEMBL3308147
DR   ChEMBL-Targets; CHEMBL2366253
DR   Cosmic; 906800
DR   Cosmic; 1037742
DR   Cosmic; 1130252
DR   Cosmic; 1191693
DR   Cosmic; 1524788
DR   Cosmic; 2396142
DR   Cosmic; 2427693
DR   Cosmic; 2649230
DR   Cosmic-CLP; 906800
DR   DepMap; ACH-000070
DR   DSMZ; ACC-42
DR   DSMZCellDive; ACC-42
DR   EGA; EGAS00001000978
DR   GDSC; 906800
DR   GEO; GSM236777
DR   GEO; GSM236813
DR   GEO; GSM886843
DR   GEO; GSM887907
DR   GEO; GSM1669562
DR   IARC_TP53; 21153
DR   IZSLER; BS TCL 241
DR   LiGeA; CCLE_726
DR   LINCS_LDP; LCL-1042
DR   Lonza; 235
DR   PharmacoDB; 697_26_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_0079
DR   Wikidata; Q54604500
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=6982733;
RX   PubMed=7630190;
RX   PubMed=7888679;
RX   PubMed=9108419;
RX   PubMed=9823951;
RX   PubMed=10490826;
RX   PubMed=11021758;
RX   PubMed=11843816;
RX   PubMed=15843827;
RX   PubMed=20164919;
RX   PubMed=20519628;
RX   PubMed=20575032;
RX   PubMed=22460905;
RX   PubMed=25984343;
RX   PubMed=27397505;
RX   PubMed=30285677;
RX   PubMed=30629668;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31160637;
RX   PubMed=31978347;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: LL-100 blood cancer cell line panel.
CC   Doubling time: 40 hours (PubMed=25984343); ~30-40 hours (DSMZ).
CC   HLA typing: A*02:01:01,25:01:01; B*07:02:01,15:01:01; C*03:03:01,07:02:01; DPA1*01:03:01,01:03:01; DPB1*04:01:01,02:01:02; DQA1*01:01:01,01:01:01; DQB1*05:01:01,05:01:01; DRA*01:01:01,01:01:01; DRB1*01:01:01,01:01:01 (DSMZ).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Gene fusion; HGNC; 8632; PBX1 + HGNC; 11633; TCF3; Name(s)=TCF3-PBX1; E2A-PBX1 (PubMed=11843816; PubMed=15843827; DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: shRNA library screening.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=0.56%; Native American=0.55%; East Asian, North=0%; East Asian, South=0%; South Asian=0%; European, North=65.87%; European, South=33.02% (PubMed=30894373).
CC   Derived from sampling site: Bone marrow.
ST   Source(s): Cosmic-CLP; DSMZ
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D13S317: 11,12
ST   D16S539: 11,12
ST   D18S51: 16
ST   D19S433: 12,14
ST   D21S11: 28,32.2
ST   D2S1338: 20,21
ST   D3S1358: 16,18
ST   D5S818: 11,13
ST   D7S820: 10,11
ST   D8S1179: 13
ST   FGA: 20,23
ST   Penta D: 10,13
ST   Penta E: 7,10
ST   TH01: 8,9
ST   TPOX: 8,11
ST   vWA: 16,18
DI   NCIt; C9140; Childhood B acute lymphoblastic leukemia
DI   NCIt; C80347; B acute lymphoblastic leukemia with t(1;19)(q23;p13.3) E2A-PBX1 (TCF3-PBX1)
DI   ORDO; Orphanet_585956; B-lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3)
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Male
AG   12Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 22-09-22; Version: 36
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=6982733; DOI=10.1182/blood.V60.6.1305.1305;
RA   Findley H.W. Jr., Cooper M.D., Kim T.H., Alvarado C., Ragab A.H.;
RT   "Two new acute lymphoblastic leukemia cell lines with early B-cell
RT   phenotypes.";
RL   Blood 60:1305-1309(1982).
//
RX   PubMed=7630190;
RA   Zhou M., Gu L., James C.D., He J., Yeager A.M., Smith S.D.,
RA   Findley H.W.;
RT   "Homozygous deletions of the CDKN2 (MTS1/p16ink4) gene in cell lines
RT   established from children with acute lymphoblastic leukemia.";
RL   Leukemia 9:1159-1161(1995).
//
RX   PubMed=7888679; DOI=10.1182/blood.V85.6.1608.bloodjournal8561608;
RA   Zhou M., Yeager A.M., Smith S.D., Findley H.W.;
RT   "Overexpression of the MDM2 gene by childhood acute lymphoblastic
RT   leukemia cells expressing the wild-type p53 gene.";
RL   Blood 85:1608-1614(1995).
//
RX   PubMed=9108419; DOI=10.1182/blood.V89.8.2986;
RA   Findley H.W., Gu L., Yeager A.M., Zhou M.;
RT   "Expression and regulation of Bcl-2, Bcl-xl, and Bax correlate with
RT   p53 status and sensitivity to apoptosis in childhood acute
RT   lymphoblastic leukemia.";
RL   Blood 89:2986-2993(1997).
//
RX   PubMed=9823951; DOI=10.1038/sj.leu.2401198;
RA   Zhou M., Gu L., Yeager A.M., Findley H.W.;
RT   "Sensitivity to Fas-mediated apoptosis in pediatric acute
RT   lymphoblastic leukemia is associated with a mutant p53 phenotype and
RT   absence of Bcl-2 expression.";
RL   Leukemia 12:1756-1763(1998).
//
RX   PubMed=10490826; DOI=10.1038/sj.onc.1202874;
RA   Fu X., McGrath S., Pasillas M., Nakazawa S., Kamps M.P.;
RT   "EB-1, a tyrosine kinase signal transduction gene, is
RT   transcriptionally activated in the t(1;19) subset of pre-B ALL, which
RT   express oncoprotein E2a-Pbx1.";
RL   Oncogene 18:4920-4929(1999).
//
RX   PubMed=11021758; DOI=10.1038/sj.leu.2401891;
RA   Majka M., Rozmyslowicz T., Honczarenko M., Ratajczak J., Wasik M.A.,
RA   Gaulton G.N., Ratajczak M.Z.;
RT   "Biological significance of the expression of HIV-related chemokine
RT   coreceptors (CCR5 and CXCR4) and their ligands by human hematopoietic
RT   cell lines.";
RL   Leukemia 14:1821-1832(2000).
//
RX   PubMed=11843816; DOI=10.1046/j.1365-2141.2001.03190.x;
RA   Curry J.D., Glaser M.C., Smith M.T.;
RT   "Real-time reverse transcription polymerase chain reaction detection
RT   and quantification of t(1;19) (E2A-PBX1) fusion genes associated with
RT   leukaemia.";
RL   Br. J. Haematol. 115:826-830(2001).
//
RX   PubMed=15843827; DOI=10.1038/sj.leu.2403749;
RA   Andersson A., Eden P., Lindgren D., Nilsson J., Lassen C., Heldrup J.,
RA   Fontes M., Borg A., Mitelman F., Johansson B., Hoglund M.,
RA   Fioretos T.;
RT   "Gene expression profiling of leukemic cell lines reveals conserved
RT   molecular signatures among subtypes with specific genetic
RT   aberrations.";
RL   Leukemia 19:1042-1050(2005).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20519628; DOI=10.1182/blood-2009-09-244673;
RA   Hirose K., Inukai T., Kikuchi J., Furukawa Y., Ikawa T., Kawamoto H.,
RA   Oram S.H., Gottgens B., Kiyokawa N., Miyagawa Y., Okita H.,
RA   Akahane K., Zhang X., Kuroda I., Honna H., Kagami K., Goi K.,
RA   Kurosawa H., Look A.T., Matsui H., Inaba T., Sugita K.;
RT   "Aberrant induction of LMO2 by the E2A-HLF chimeric transcription
RT   factor and its implication in leukemogenesis of B-precursor ALL with
RT   t(17;19).";
RL   Blood 116:962-970(2010).
//
RX   PubMed=20575032; DOI=10.1002/ajh.21738;
RA   Inukai T., Zhang X.-R., Kameyama T., Suzuki Y., Yoshikawa K., Kuroda I.,
RA   Nemoto A., Akahane K., Sato H., Goi K., Nakamoto K., Hamada J.-I.,
RA   Tada M., Moriuchi T., Sugita K.;
RT   "A specific linkage between the incidence of TP53 mutations and type
RT   of chromosomal translocations in B-precursor acute lymphoblastic
RT   leukemia cell lines.";
RL   Am. J. Hematol. 85:535-537(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035-140035(2014).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30285677; DOI=10.1186/s12885-018-4840-5;
RA   Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X.,
RA   Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H.,
RA   Koeffler H.P.;
RT   "Profiling the B/T cell receptor repertoire of lymphocyte derived cell
RT   lines.";
RL   BMC Cancer 18:940.1-940.13(2018).
//
RX   PubMed=30629668; DOI=10.1371/journal.pone.0210404;
RA   Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.;
RT   "Screening human cell lines for viral infections applying RNA-Seq data
RT   analysis.";
RL   PLoS ONE 14:E0210404-E0210404(2019).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218-8218(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//